Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Improvement of pyrazolo[3,4-d]pyrimidines pharmacokinetic properties: nanosystem approaches for drug delivery
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-02-22
DOI
10.1038/srep21509
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- SRC Family Kinase Inhibition Through a New Pyrazolo[3,4-d]Pyrimidine Derivative as a Feasible Approach for Glioblastoma Treatment
- (2015) Elisa Ceccherini et al. JOURNAL OF CELLULAR BIOCHEMISTRY
- SRC family kinase (SFK) inhibition reduces rhabdomyosarcoma cell growth in vitro and in vivo and triggers p38 MAP kinase-mediated differentiation
- (2015) Nadia Casini et al. Oncotarget
- A clinical update of using albumin as a drug vehicle — A commentary
- (2014) Felix Kratz JOURNAL OF CONTROLLED RELEASE
- Combining X-ray Crystallography and Molecular Modeling toward the Optimization of Pyrazolo[3,4-d]pyrimidines as Potent c-Src Inhibitors Active in Vivo against Neuroblastoma
- (2014) Cristina Tintori et al. JOURNAL OF MEDICINAL CHEMISTRY
- Exploring the Chemical Space around the Privileged Pyrazolo[3,4-d]pyrimidine Scaffold: Toward Novel Allosteric Inhibitors of T315I-Mutated Abl
- (2014) Giulia Vignaroli et al. ACS Combinatorial Science
- A nontoxic disulfide bond reducing method for lipophilic drug-loaded albumin nanoparticle preparation: Formation dynamics, influencing factors and formation mechanisms investigation
- (2013) Liqun Jiang et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Design, Synthesis, and Biological Evaluation of Pyrazolo[3,4-d]pyrimidines Active in Vivo on the Bcr-Abl T315I Mutant
- (2013) Marco Radi et al. JOURNAL OF MEDICINAL CHEMISTRY
- Membrane Lipidome Reorganization Correlates with the Fate of Neuroblastoma Cells Supplemented with Fatty Acids
- (2013) Andrea Bolognesi et al. PLoS One
- Pyrazolo[3,4-d]pyrimidine Prodrugs: Strategic Optimization of the Aqueous Solubility of Dual Src/Abl Inhibitors
- (2013) Giulia Vignaroli et al. ACS Medicinal Chemistry Letters
- Comparison of Extruded and Sonicated Vesicles for Planar Bilayer Self-Assembly
- (2013) Nam-Joon Cho et al. Materials
- Liposomal drug delivery systems: From concept to clinical applications
- (2012) Theresa M. Allen et al. ADVANCED DRUG DELIVERY REVIEWS
- Tyrosine Kinase Blockers: New Hope for Successful Cancer Therapy
- (2012) Dariusz Pytel et al. Anti-Cancer Agents in Medicinal Chemistry
- A combined targeted/phenotypic approach for the identification of new antiangiogenics agents active on a zebrafish model: From in silico screening to cyclodextrin formulation
- (2012) Marco Radi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Development of treatment strategies for advanced neuroblastoma
- (2012) Junichi Hara International Journal of Clinical Oncology
- Doxil® — The first FDA-approved nano-drug: Lessons learned
- (2012) Yechezkel (Chezy) Barenholz JOURNAL OF CONTROLLED RELEASE
- Antitumor Activity of Saracatinib (AZD0530), a c-Src/Abl Kinase Inhibitor, Alone or in Combination with Chemotherapeutic Agents in Gastric Cancer
- (2012) H.-J. Nam et al. MOLECULAR CANCER THERAPEUTICS
- Identification of potent c-Src inhibitors strongly affecting the proliferation of human neuroblastoma cells
- (2011) Marco Radi et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Albumin-based nanoparticles as potential controlled release drug delivery systems
- (2011) Ahmed O. Elzoghby et al. JOURNAL OF CONTROLLED RELEASE
- Current Status of Src Inhibitors in Solid Tumor Malignancies
- (2011) L. N. Puls et al. ONCOLOGIST
- Discovery of novel purine derivatives with potent and selective inhibitory activity against c-Src tyrosine kinase
- (2010) He Huang et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Antiproliferative and pro-apoptotic effects afforded by novel Src-kinase inhibitors in human neuroblastoma cells
- (2010) Michele Navarra et al. BMC CANCER
- Criteria for evaluation of disease extent by 123I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force
- (2010) K K Matthay et al. BRITISH JOURNAL OF CANCER
- 2-Hydroxypropyl-β-cyclodextrin strongly improves water solubility and anti-proliferative activity of pyrazolo[3,4-d]pyrimidines Src-Abl dual inhibitors
- (2010) Elena Dreassi et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Novel dual Src/Abl inhibitors for hematologic and solid malignancies
- (2010) Silvia Schenone et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Nanoparticulate drug delivery systems for cancer chemotherapy
- (2010) Ranendra N. Saha et al. MOLECULAR MEMBRANE BIOLOGY
- Src kinase family inhibitor PP2 induces aggregation and detachment of neuroblastoma cells and inhibits cell growth in a PI3 kinase/Akt pathway-independent manner
- (2010) Tomoro Hishiki et al. PEDIATRIC SURGERY INTERNATIONAL
- Activity of tyrosine kinase inhibitor Dasatinib in neuroblastoma cellsin vitroand in orthotopic mouse model
- (2009) Roberta Vitali et al. INTERNATIONAL JOURNAL OF CANCER
- Design and synthesis of 7-alkoxy-4-heteroarylamino-3-quinolinecarbonitriles as dual inhibitors of c-Src kinase and nitric oxide synthase
- (2008) Xin Cao et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Observation and modelling of capillary flow occlusion resulting from the capture of superparamagnetic nanoparticles in a magnetic field
- (2008) B. Hallmark et al. CHEMICAL ENGINEERING SCIENCE
- Src and focal adhesion kinase as therapeutic targets in cancer
- (2008) Valerie G Brunton et al. CURRENT OPINION IN PHARMACOLOGY
- Development of novel benzotriazines for drug discovery
- (2008) Moorthy SS Palanki et al. Expert Opinion on Drug Discovery
- Antiproliferative and proapoptotic activities of new pyrazolo[3,4-d]pyrimidine derivative Src kinase inhibitors in human osteosarcoma cells
- (2008) Adriano Spreafico et al. FASEB JOURNAL
- Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles
- (2008) Felix Kratz JOURNAL OF CONTROLLED RELEASE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now